Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
© 2024. The Author(s)..
INTRODUCTION: Talquetamab, a bispecific antibody targeting GPRC5D × CD3, is approved for the treatment of patients with triple-class -exposed (TCE) relapsed/refractory multiple myeloma (RRMM) on the basis of the results from the phase I/II MonumenTAL-1 trial. The relative effectiveness of talquetamab vs. real-world physician's choice of therapy (RWPC) was assessed using adjusted comparisons.
METHODS: An external control arm for MonumenTAL-1 (subcutaneously administered talquetamab 0.4 mg/kg weekly [QW] and 0.8 mg/kg every other week [Q2W]) was created from two observational real-world studies: LocoMMotion and MoMMent. Imbalances in baseline covariates were adjusted using inverse probability weighting. The relative effectiveness of talquetamab vs. RWPC was estimated for overall response rate (ORR), ≥ very good partial response (VGPR), and ≥ complete response (CR); odds ratios and relative response ratios (RRs) were derived from weighted logistic regression. Hazard ratios (HRs) for duration of response (DOR), progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS) were estimated using a weighted Cox proportional hazards model.
RESULTS: After reweighting, baseline characteristics were balanced across cohorts. In adjusted comparisons, patients treated with talquetamab QW (n = 143) had significantly improved outcomes vs. RWPC; RRs were ORR 2.67, p < 0.0001; ≥ VGPR 4.70, p < 0.0001; ≥ CR 78.05, p = 0.0002; and HRs were PFS 0.52, p < 0.0001; TTNT 0.48, p < 0.0001; OS 0.36, p < 0.0001. Patients treated with talquetamab Q2W (n = 145) also had significantly improved outcomes vs. RWPC; RRs were ORR 2.62, p < 0.0001; ≥ VGPR 5.04, p < 0.0001; ≥ CR 101.14, p = 0.0002; and HRs were PFS 0.40, p < 0.0001; TTNT 0.39, p < 0.0001; OS 0.37, p < 0.0001.
CONCLUSION: Effectiveness of talquetamab for both schedules was significantly better than RWPC for ORR, ≥ VGPR, ≥ CR, PFS, OS, and TTNT, highlighting its clinical benefit for patients with TCE RRMM.
TRIAL REGISTRATION: MonumenTAL-1, ClinicalTrials.gov identifier NCT03399799/NCT04634552; LocoMMotion, ClinicalTrials.gov identifier NCT04035226; MoMMent, ClinicalTrials.gov identifier NCT05160584.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Advances in therapy - 41(2024), 4 vom: 25. März, Seite 1576-1593 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Einsele, Hermann [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 26.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT05160584, NCT04035226, NCT04634552 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12325-024-02797-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368923487 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368923487 | ||
| 003 | DE-627 | ||
| 005 | 20240326235537.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-024-02797-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM368923487 | ||
| 035 | |a (NLM)38402374 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Einsele, Hermann |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT05160584, NCT04035226, NCT04634552 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a INTRODUCTION: Talquetamab, a bispecific antibody targeting GPRC5D × CD3, is approved for the treatment of patients with triple-class -exposed (TCE) relapsed/refractory multiple myeloma (RRMM) on the basis of the results from the phase I/II MonumenTAL-1 trial. The relative effectiveness of talquetamab vs. real-world physician's choice of therapy (RWPC) was assessed using adjusted comparisons | ||
| 520 | |a METHODS: An external control arm for MonumenTAL-1 (subcutaneously administered talquetamab 0.4 mg/kg weekly [QW] and 0.8 mg/kg every other week [Q2W]) was created from two observational real-world studies: LocoMMotion and MoMMent. Imbalances in baseline covariates were adjusted using inverse probability weighting. The relative effectiveness of talquetamab vs. RWPC was estimated for overall response rate (ORR), ≥ very good partial response (VGPR), and ≥ complete response (CR); odds ratios and relative response ratios (RRs) were derived from weighted logistic regression. Hazard ratios (HRs) for duration of response (DOR), progression-free survival (PFS), time to next treatment (TTNT), and overall survival (OS) were estimated using a weighted Cox proportional hazards model | ||
| 520 | |a RESULTS: After reweighting, baseline characteristics were balanced across cohorts. In adjusted comparisons, patients treated with talquetamab QW (n = 143) had significantly improved outcomes vs. RWPC; RRs were ORR 2.67, p < 0.0001; ≥ VGPR 4.70, p < 0.0001; ≥ CR 78.05, p = 0.0002; and HRs were PFS 0.52, p < 0.0001; TTNT 0.48, p < 0.0001; OS 0.36, p < 0.0001. Patients treated with talquetamab Q2W (n = 145) also had significantly improved outcomes vs. RWPC; RRs were ORR 2.62, p < 0.0001; ≥ VGPR 5.04, p < 0.0001; ≥ CR 101.14, p = 0.0002; and HRs were PFS 0.40, p < 0.0001; TTNT 0.39, p < 0.0001; OS 0.37, p < 0.0001 | ||
| 520 | |a CONCLUSION: Effectiveness of talquetamab for both schedules was significantly better than RWPC for ORR, ≥ VGPR, ≥ CR, PFS, OS, and TTNT, highlighting its clinical benefit for patients with TCE RRMM | ||
| 520 | |a TRIAL REGISTRATION: MonumenTAL-1, ClinicalTrials.gov identifier NCT03399799/NCT04634552; LocoMMotion, ClinicalTrials.gov identifier NCT04035226; MoMMent, ClinicalTrials.gov identifier NCT05160584 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a LocoMMotion | |
| 650 | 4 | |a MoMMent | |
| 650 | 4 | |a MonumenTAL-1 | |
| 650 | 4 | |a Talquetamab | |
| 650 | 4 | |a Triple-class-exposed relapsed/refractory multiple myeloma | |
| 700 | 1 | |a Moreau, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Bahlis, Nizar |e verfasserin |4 aut | |
| 700 | 1 | |a Bhutani, Manisha |e verfasserin |4 aut | |
| 700 | 1 | |a Vincent, Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Karlin, Lionel |e verfasserin |4 aut | |
| 700 | 1 | |a Perrot, Aurore |e verfasserin |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |e verfasserin |4 aut | |
| 700 | 1 | |a van de Donk, Niels W C J |e verfasserin |4 aut | |
| 700 | 1 | |a Ocio, Enrique M |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Lopez, Joaquin |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Otero, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Dytfeld, Dominik |e verfasserin |4 aut | |
| 700 | 1 | |a Diels, Joris |e verfasserin |4 aut | |
| 700 | 1 | |a Strulev, Vadim |e verfasserin |4 aut | |
| 700 | 1 | |a Haddad, Imene |e verfasserin |4 aut | |
| 700 | 1 | |a Renaud, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Ammann, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Cabrieto, Jedelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Perualila, Nolen |e verfasserin |4 aut | |
| 700 | 1 | |a Gan, Ryan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Youyi |e verfasserin |4 aut | |
| 700 | 1 | |a Parekh, Trilok |e verfasserin |4 aut | |
| 700 | 1 | |a Albrecht, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Weisel, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Mateos, Maria-Victoria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d 1990 |g 41(2024), 4 vom: 25. März, Seite 1576-1593 |w (DE-627)NLM085859427 |x 1865-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:4 |g day:25 |g month:03 |g pages:1576-1593 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12325-024-02797-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 4 |b 25 |c 03 |h 1576-1593 | ||